- In October 2023, Aurion Biotech initiated a phase 1/2 clinical trial in the United States to evaluate its cell therapy aimed at treating corneal edema. This study marks a significant advancement in exploring innovative treatment options for this eye condition. The trial's progression will be closely monitored as it seeks to demonstrate the therapy's safety and efficacy in patients
- In October 2023, Nkarta, Inc. received FDA approval for its Investigational New Drug (IND) application to study NKX019, an allogeneic CAR NK cell therapy targeting CD19. This therapy aims to provide a novel treatment option for lupus nephritis, a challenging autoimmune condition. The approval marks a crucial step in advancing NKX019 towards clinical trials, where its effectiveness and safety will be assessed
- In June 2023, Vertex Pharmaceuticals Incorporated partnered with Lonza to establish a joint venture aimed at enhancing the production of Vertex's investigational stem cell therapies. This collaboration specifically targets treatments for Type 1 Diabetes (T1D), concentrating on the clinical trial programs VX-880 and VX-264. The initiative is expected to streamline manufacturing processes and support the advancement of these promising therapies
- In May 2023, Johnson & Johnson entered into a global collaboration and licensing agreement with Cellular Biomedicine Group to co-develop advanced CAR-T therapies. This partnership aims to innovate and enhance the effectiveness of CAR-T treatments, reflecting both companies' commitment to advancing cancer therapies. The collaboration is expected to accelerate the development of these next-generation therapies in the oncology space
- In March 2023, Adaptimmune Therapeutics plc and TCR2 Therapeutics announced a strategic partnership aimed at establishing a leading cell therapy organization focused on treating solid tumors. This alliance is designed to leverage each company's expertise and resources to advance innovative therapies in this challenging area of oncology. The collaboration reflects a shared commitment to improving treatment options and outcomes for patients with solid tumor cancers
Frequently Asked Questions
The market is segmented based on Segmentation, By Technology (Somatic Cell Technology, Cell Immortalization Technology, Viral Vector Technology, Genome Editing Technology, Cell Plasticity Technology, and Three-Dimensional Technology), Type (Autologous and Allogeneic), Cell Type (Stem Cell and Non-Stem Cell), Cell Source (iPSCs, Bone Marrow, Umbilical Cord Blood-Derived Cells, Adipose Tissues, and Neural Stem Cell), Application (Musculoskeletal, Cardiovascular, Gastrointestinal, Neurological, Oncology, Dermatology, Wounds and Injuries, Ocular, and Others), End-User (Hospitals and Clinics, Regenerative Medicine Centres, Diagnostic and Research Centres, and Others) – Industry Trends and Forecast to 2031
.
The Global Cell Therapy Market size was valued at USD 17.75 USD Million in 2023.
The Global Cell Therapy Market is projected to grow at a CAGR of 19.2% during the forecast period of 2024 to 2031.
The major players operating in the market include Vericel Corporation, Kolon TissueGene , JCR Pharmaceuticals Co. , MEDIPOST, Osiris, Stemedica Cell Technologies , NuVasive , Fibrocell Science , Cellectis, BioNTech IMFS, Pluristem, Praxis Pharmaceutical, Genzyme Corporation, Advanced Tissue, Cells for Cells, PHARMICELL Co. Ltd, ANTEROGEN.CO., Novartis AG, GlaxoSmithKline plc, CELGENE CORPORATION, Bone Therapeutics, Cell Therapies, Celyad, Regen BioPharma, Cellular Therapeutics Ltd, TxCell, Advancells.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
